Capital Analysts LLC’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $217K | Hold |
413
| – | – | 0.01% | 537 |
|
|
2025
Q1 | $262K | Buy |
413
+16
| +4% | +$10.2K | 0.01% | 480 |
|
|
2024
Q4 | $283K | Buy |
397
+69
| +21% | +$49.2K | 0.01% | 419 |
|
|
2024
Q3 | $345K | Sell |
328
-7
| -2% | -$7.36K | 0.01% | 379 |
|
|
2024
Q2 | $352K | Buy |
335
+40
| +14% | +$42K | 0.02% | 379 |
|
|
2024
Q1 | $284K | Buy |
295
+1
| +0.3% | +$963 | 0.01% | 386 |
|
|
2023
Q4 | $258K | Sell |
294
-1
| -0.3% | -$878 | 0.01% | 391 |
|
|
2023
Q3 | $243K | Buy |
295
+12
| +4% | +$9.89K | 0.01% | 373 |
|
|
2023
Q2 | $203K | Sell |
283
-8
| -3% | -$5.74K | 0.01% | 376 |
|
|
2023
Q1 | $239K | Sell |
291
-23
| -7% | -$18.9K | 0.01% | 359 |
|
|
2022
Q4 | $227K | Sell |
314
-29
| -8% | -$21K | 0.01% | 382 |
|
|
2022
Q3 | $236K | Sell |
343
-35
| -9% | -$24.1K | 0.02% | 337 |
|
|
2022
Q2 | $223K | Buy |
378
+12
| +3% | +$7.08K | 0.02% | 333 |
|
|
2022
Q1 | $256K | Sell |
366
-97
| -21% | -$67.8K | 0.02% | 319 |
|
|
2021
Q4 | $292K | Buy |
463
+17
| +4% | +$10.7K | 0.02% | 309 |
|
|
2021
Q3 | $270K | Buy |
446
+46
| +12% | +$27.8K | 0.02% | 311 |
|
|
2021
Q2 | $223K | Sell |
400
-2
| -0.5% | -$1.12K | 0.02% | 326 |
|
|
2021
Q1 | $190K | Buy |
402
+27
| +7% | +$12.8K | 0.01% | 348 |
|
|
2020
Q4 | $181K | Sell |
375
-440
| -54% | -$212K | 0.02% | 252 |
|
|
2020
Q3 | $456K | Buy |
815
+380
| +87% | +$213K | 0.04% | 198 |
|
|
2020
Q2 | $271K | Sell |
435
-55
| -11% | -$34.3K | 0.03% | 208 |
|
|
2020
Q1 | $239K | Buy |
490
+55
| +13% | +$26.8K | 0.03% | 195 |
|
|
2019
Q4 | $163K | Buy |
+435
| New | +$163K | 0.02% | 250 |
|